IR News

CHEPLAPHARM acquires rights to Rivotril®


Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.



"As a successful start…

Read more  /  pdf

CHEPLAPHARM completes it´s largest acquisition so far


Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda



Read more  /  pdf

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets


Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus


CHEPLAPHARM has held the rights for…

Read more  /  pdf


CHEPLAPHARM proves its vigour


Cheplapharm successfully closes the first project with LEO Pharma


This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

Read more  /  pdf

CHEPLAPHARM closes another product portfolio acquisition


This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

Read more  /  pdf

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Read more  /  pdf

CHEPLAPHARM - Quarterly Update Call Q4 / FY 2019

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019

| Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST

Read more  /  pdf

Corona Virus (COVID-19) Impact on CHEPLAPHARM activities

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential

impact on the various Supply Chains and is committed…

Read more  /  pdf

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,…

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of…

Read more  /  pdf

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Read more  /  pdf


CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year.…

Read more  /  pdf


CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in…

Read more  /  pdf

CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

Read more  /  pdf

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

Read more  /  pdf